Health Canada
Symbol of the Government of Canada

Common menu bar links

Drugs and Health Products

Consultation on Health Product Transparency Initiatives

Warning This content was archived on March 08, 2016.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.

Notice to the reader: The online consultation is now closed.

Health Canada is seeking feedback from stakeholders on the next steps regarding several of its transparency initiatives for health products. The initiatives to be discussed are the following:

Health Canada is committed to greater transparency and openness in order to further strengthen understanding of our regulatory decisions. We launched the Regulatory Transparency and Openness Framework (RTOF) in 2014 to support this commitment. The initiatives listed above are part of our commitments under the RTOF, and each provides Canadians with useful information to support informed treatment choices for themselves or others.

The consultation is in the form of an online questionnaire. Each section describes one of the initiatives and is followed by questions on that subject.

The feedback will be used for further development of the initiatives identified above.

Who can participate in this consultation?

 Health Canada welcomes the participation of all interested parties in this consultation.

How to get involved

This consultation will be open from January 25 to February 19, 2016.

Please select the link titled "consultation document" below to begin the online questionnaire.

Consultation on Health Product Transparency Initiatives

For more information

For general questions and concerns, please contact:

Health Canada
Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Ottawa, Ontario
K1A 0K9

Facsimile: (613) 941-1812
E-mail: Policy_Bureau_Enquiries@hc-sc.gc.ca

Reporting to Canadians

A summary of the results from the consultation will be made available.